SpaceFOMO
SpaceFOMO
Feed
Mission Success / BioOrbit

BioOrbit completes six-week ISS protein-crystallisation experiment

BioOrbit completed a six-week experiment aboard the International Space Station to produce protein crystals in microgravity. The company used a specially developed manufacturing unit to grow crystals that could enable highly concentrated cancer medicines suitable for subcutaneous injection rather than intravenous infusion. UKRI announced the successful completion on October 23, 2026, describing it as an important step toward commercial pharmaceutical manufacturing in space.

Why it matters

The completed ISS experiment is BioOrbit's most concrete proof point to date and moves the company from concept toward an orbital manufacturing pathway. Commercialisation still depends on demonstrating repeatable pharmaceutical-grade production, regulatory acceptance, and a viable return-and-manufacturing cadence.

The numbers

Experiment duration
6 weeks

completed a six-week experiment aboard the International Space Station

Source

Coverage

1 report
  1. ADS Advance ·

    Cancer drugs made in space: BioOrbit's ISS breakthrough

    BioOrbit completed a six-week experiment aboard the International Space Station to grow protein crystals in microgravity using its purpose-built manufacturing unit. UKRI announced the successful completion on October 23, and the company aims to use the approach to develop highly concentrated cancer medicines suitable for home injection rather than hospital infusion.

    79

AI-assisted summary of 1 report; numbers link to their source. Spot an error? Tell us.

Veenie.Space Telemetry

Simulate BioOrbit hardware

BioOrbit completed a six-week experiment aboard the International Space Station to produce protein c

Get launch moments in your inbox

A weekly digest of the moments you'd regret missing. Starting soon: get on the list.